中华医学杂志
中華醫學雜誌
중화의학잡지
National Medical Journal of China
2010年
37期
2636-2639
,共4页
李永锋%胡祎%林鹏%郑斌%罗孔嘉%杨弘%杨浩贤%王军业%戎铁华%傅剑华
李永鋒%鬍祎%林鵬%鄭斌%囉孔嘉%楊弘%楊浩賢%王軍業%戎鐵華%傅劍華
리영봉%호의%림붕%정빈%라공가%양홍%양호현%왕군업%융철화%부검화
食管肿瘤/外科手术%隆突下%淋巴结清扫
食管腫瘤/外科手術%隆突下%淋巴結清掃
식관종류/외과수술%륭돌하%림파결청소
Esophagus neoplasm/surgical operation%Subcarinal lymph nodes%Lymphadenectomy
目的 本研究拟探讨胸段食管癌是否需要常规进行隆突下淋巴结清扫.方法 回顾性分析2000年1月至2004年12月中山大学肿瘤防治中心连续收治676例胸段食管癌患者的隆突下淋巴结的转移状态与临床病理因素的关系,进一步比较分析有或无清扫隆突下淋巴结对围术期并发症、术后生存期的影响.结果 全组676例,其中492例有清扫隆突下淋巴结,其转移率为10.4%;胸上、中、下段食管癌隆突下淋巴结转移率分别为0%、13.2%、6.8%,P=0.001;Tis、T1、T2、T3和T4的降突下淋巴结转移率分别为0%、0%、6.5%、13.3%和28.6%,P=0.008;有隆突下淋巴结转移者均伴有区域淋巴结转移,无单独隆突下淋巴结转移者.清扫与未清扫隆突下淋巴结的术后并发症总发生率分别为36.8%、26.6%,P=0.013,其中肺部并发症的发生率分别为22.2%、14.1%,P=0.020.生存分析显示:N0患者中,隆突下淋巴结未清扫组与清扫组的5年生存率分别为50.9%、62.8%,P=0.083;N1患者中,隆突下淋巴结未清扫组与清扫组的5年生存率分别为14.7%、29.3%,P=0.112;隆突下淋巴结阳性者与阴性者的5年生存率分别为22.6%、31.7%,P=0.142.结论 局部早期及胸上段食管癌可以不常规实施隆突下淋巴结清扫术;胸中、下段食管癌局部侵犯明显,应进行隆突下淋巴结清扫术.
目的 本研究擬探討胸段食管癌是否需要常規進行隆突下淋巴結清掃.方法 迴顧性分析2000年1月至2004年12月中山大學腫瘤防治中心連續收治676例胸段食管癌患者的隆突下淋巴結的轉移狀態與臨床病理因素的關繫,進一步比較分析有或無清掃隆突下淋巴結對圍術期併髮癥、術後生存期的影響.結果 全組676例,其中492例有清掃隆突下淋巴結,其轉移率為10.4%;胸上、中、下段食管癌隆突下淋巴結轉移率分彆為0%、13.2%、6.8%,P=0.001;Tis、T1、T2、T3和T4的降突下淋巴結轉移率分彆為0%、0%、6.5%、13.3%和28.6%,P=0.008;有隆突下淋巴結轉移者均伴有區域淋巴結轉移,無單獨隆突下淋巴結轉移者.清掃與未清掃隆突下淋巴結的術後併髮癥總髮生率分彆為36.8%、26.6%,P=0.013,其中肺部併髮癥的髮生率分彆為22.2%、14.1%,P=0.020.生存分析顯示:N0患者中,隆突下淋巴結未清掃組與清掃組的5年生存率分彆為50.9%、62.8%,P=0.083;N1患者中,隆突下淋巴結未清掃組與清掃組的5年生存率分彆為14.7%、29.3%,P=0.112;隆突下淋巴結暘性者與陰性者的5年生存率分彆為22.6%、31.7%,P=0.142.結論 跼部早期及胸上段食管癌可以不常規實施隆突下淋巴結清掃術;胸中、下段食管癌跼部侵犯明顯,應進行隆突下淋巴結清掃術.
목적 본연구의탐토흉단식관암시부수요상규진행륭돌하림파결청소.방법 회고성분석2000년1월지2004년12월중산대학종류방치중심련속수치676례흉단식관암환자적륭돌하림파결적전이상태여림상병리인소적관계,진일보비교분석유혹무청소륭돌하림파결대위술기병발증、술후생존기적영향.결과 전조676례,기중492례유청소륭돌하림파결,기전이솔위10.4%;흉상、중、하단식관암륭돌하림파결전이솔분별위0%、13.2%、6.8%,P=0.001;Tis、T1、T2、T3화T4적강돌하림파결전이솔분별위0%、0%、6.5%、13.3%화28.6%,P=0.008;유륭돌하림파결전이자균반유구역림파결전이,무단독륭돌하림파결전이자.청소여미청소륭돌하림파결적술후병발증총발생솔분별위36.8%、26.6%,P=0.013,기중폐부병발증적발생솔분별위22.2%、14.1%,P=0.020.생존분석현시:N0환자중,륭돌하림파결미청소조여청소조적5년생존솔분별위50.9%、62.8%,P=0.083;N1환자중,륭돌하림파결미청소조여청소조적5년생존솔분별위14.7%、29.3%,P=0.112;륭돌하림파결양성자여음성자적5년생존솔분별위22.6%、31.7%,P=0.142.결론 국부조기급흉상단식관암가이불상규실시륭돌하림파결청소술;흉중、하단식관암국부침범명현,응진행륭돌하림파결청소술.
Objective Surgical resection remains the cornerstone of treatment for esophageal carcinoma. Mediastinal lymphadenectomy including subcarinal nodes has always been considered to be a reasonable extent, because of close anatomical relationship between subcarinal nodes and tracheobronchial tree. Metastatic involvement of subcarinal nodes alone is rare in esophageal carcinoma. In view of special anatomical features of subcarinal lymph nodes, it is worth exploring and discussing whether or not subcarinal lymph nodes dissection shall be routinely performed for thoracic esophageal carcinoma. Methods The data from a cohort of 676 patients with thoracic esophagus carcinoma who underwent esophagectomy with lymphadenectomy were analyzed retrospectively with respect to the impact of subcarinal lymph nodes dissection or non-dissection on the incidence of postoperative complications and patient survival. Results The rate of subcarinal lymph nodes metastasis was 10. 4%. The metastasis rates in upper, middle and lower esophageal carcinoma were 0%, 13.2% and 6. 8% respectively ( P =0. 001 ); for Tis, T1, T2, T3 and T4, they were 0%, 0%, 6. 5%, 13.3% and 28. 6% respectively ( P = 0. 008 ). The overall incidence of postoperative complications with and without subcarinal lymph nodes dissection was 36. 8% versus 26. 6%( P = 0. 013 ). And the incidence of pulmonary complications were 22. 2% versus 14. 1% ( P = 0. 020 ).Survival analysis showed that: the 5-year survival rates were 50. 9% versus 62. 8% in the groups A and B of NO patients ( P =0. 083 ); 14. 7% versus 29. 3% in N1 patients ( P =0. 112). In the group with metastasis of subcarinal lymph nodes, the 5-year survival rate was 22. 6% versus 31.7% in those without metastasis (P = 0. 142 ). Conclusion It may be unnecessary to dissect the subcarinal lymph nodes routinely for upper thoracic esophageal carcinoma. Elective subcarinal lymph nodes dissection can be planned for middle,lower, T3 or T4 thoracic esophageal carcinoma, or highly suspected subcarinal metastasis based on radiological imaging.